Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting - Candlesense
TRIS Clinical

Tris Pharma to Debut Positive Results of Intranasal (Snorting) Human Abuse Potential Study of Cebranopadol, an Investigational First-In-Class Oral Dual-NMR Agonist for the Treatment of Moderate-to-Severe Pain, at the 2025 CPDD Annual Meeting

MONMOUTH JUNCTION, N.J.--(BUSINESS WIRE)--Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today announced that the company will present intranasal human abusability data from cebranopadol, an investigational first-in-class oral dual NOP/MOP (dual-NMR) agonist, at the College on Problems of Drug Dependence (CPDD) Annual Meeting, taking place June 14-18, 2025, in New Orleans. The data will be presented in a late-breaking oral session and a poster presentation which highlig
Find similar articles on Candlesense businesswire